Bayer takes another shot at Monsanto acquisition

pharmafile | September 6, 2016 | News story | Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto 

Bayer has made another move to acquire US-based Monsanto, raising the price it is prepared to pay in an effort to snare the agrochemical and agricultural biotech.

The German chemical company says it is now prepared to pay $127.50 per share, 2% more than its previous bid, bringing its total valuation of the company to approximately $56 billion, or $65 billion including debt.  The offer falls short of some analyst predictions on how much the company will have to venture to secure the deal, with some placing the sweet spot at $135 a share.

Monsanto’s shares have declined since Bayer’s initial bid, and closed at $107.44 in New York on Friday.

Matt Fellows

Related Content

Bayer and Aignostics to collaborate for AI oncology research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …

Novo Holdings acquires BBI Group in £400 million deal

Novo Holdings, a holding company of the Novo Group, has acquired BBI Group from Exponent …

Bayer’s cardiovascular drug shows impressive Phase III results

Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events …

Latest content